Kentucky Retirement Systems Insurance Trust Fund cut its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 7.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,015 shares of the medical research company’s stock after selling 1,592 shares during the period. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Edwards Lifesciences were worth $1,913,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in EW. Crewe Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $28,000. Riverview Trust Co purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $34,000. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $34,000. Finally, Rise Advisors LLC raised its holdings in Edwards Lifesciences by 125.0% during the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after buying an additional 265 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Stock Up 4.5 %
Edwards Lifesciences stock traded up $2.67 during midday trading on Friday, reaching $62.37. The company’s stock had a trading volume of 14,111,391 shares, compared to its average volume of 5,310,790. The stock’s 50-day simple moving average is $87.98 and its 200-day simple moving average is $86.92. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.67. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $37.58 billion, a P/E ratio of 26.88, a PEG ratio of 2.31 and a beta of 1.11.
Analyst Ratings Changes
Several analysts recently weighed in on EW shares. Robert W. Baird lowered Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $102.00 to $70.00 in a report on Thursday. Evercore ISI decreased their price target on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a report on Thursday. Truist Financial lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $110.00 to $82.00 in a report on Thursday. JPMorgan Chase & Co. lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $105.00 to $72.00 in a report on Thursday. Finally, Canaccord Genuity Group decreased their price target on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $82.10.
View Our Latest Research Report on Edwards Lifesciences
Insider Transactions at Edwards Lifesciences
In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction on Monday, May 6th. The shares were bought at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 8,617 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the sale, the chief executive officer now directly owns 68,218 shares of the company’s stock, valued at $5,981,354.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders sold a total of 81,099 shares of company stock worth $7,003,553 over the last three months. 1.29% of the stock is currently owned by insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- How to Invest in Insurance Companies: A Guide
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Use the MarketBeat Dividend Calculator
- Why Call Options Volume for These 2 Stocks Spiked Together
- Do ETFs Pay Dividends? What You Need to Know
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.